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Chronic Pain, Dopamine and 




There have been several indications that pain and reward are partly mediated 
by similar neural pathways in the central nervous system, and that these common 
pathways are related to both the dopamine (DA) and the opioid systems. Several 
studies have demonstrated the analgesic effects of rewarding stimuli or activities 
on positive affective states. On the other hand, chronic pain was shown to impair 
several aspects of reward processing by possibly altering pain-reward interac-
tions. However, the precise mechanisms of the mutual pain-reward interaction are 
unclear and few studies have investigated the influence of pain on rewards and vice 
versa in humans. Therefore, we aim to summarize recent findings on the neuroana-
tomical and molecular chances associated with chronic pain conditions, particularly 
fibromyalgia syndrome (FMS) with a focus on the dopamine system. Recent 
findings on the mechanisms involved in the alterations of the brain reward circuit in 
chronic pain and FMS as well as the role of DA in the pathophysiology of FMS and 
other chronic pain conditions will be discussed. Furthermore, we aim to discuss the 
interplay between the dopaminergic reward system and depression in chronic pain, 
as the prevalence of co-morbid depression in chronic pain is quite high.
Keywords: chronic pain, dopamine, fibromyalgia, depression
1. Chronic pain and fibromyalgia
1.1 The burden associated with chronic pain
Chronic pain is defined as “a pain that persists past the normal time of healing” 
([1], p. 4). In practice, chronic pain is defined as a pain that lasts for more than 3–6 
months [1, 2]. With an estimated prevalence up to 40%, chronic pain is regarded 
as a major health problem with approximated direct and indirect costs reaching to 
5% of the gross national product in western European countries [3]. Also in term 
of prevalence, chronic pain represents an important public health issue. A recent 
epidemiological survey indicated that almost one in five Europeans report having 
experienced moderate to severe pain in the last month and at least twice a week [3]. 
Chronic pain significantly decreases individuals’ health status and quality of life 
[4] and is linked with a wide range of physical and mental problems such as sleep 
disorders, depression, anxiety disorders, and alcohol or substance abuse, either as 
antecedent conditions or as consequences of the development of pain [5]. The fact 
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that the number of people suffering from a chronic pain condition is steadily rising 
[6], in spite of the overall improving standards of health care, emphasizes the 
urgent need for novel insights informing better diagnosis, prevention and treatment 
of patients with chronic pain.
1.2 The specific case of Fibromyalgia
Fibromyalgia syndrome (FMS) is a chronic, painful musculoskeletal disorder 
characterized by widespread pain, accompanied by a broad spectrum of associ-
ated somatic and psychological manifestations, including fatigue, sleep distur-
bances, stiffness, anxiety and cognitive dysfunction [7, 8]. The current diagnostic 
criteria of FMS emphasize the behavioral and psychological aspects of the disease 
and are based on self-reported evaluation of symptoms [9]. This is an important 
change compared to the previous diagnostic criteria that required tender point 
examination [8], while the new criteria are essentially based on self-reported 
symptoms. The development of new diagnostic criteria for FMS is related to the 
evolution of the understanding of the underlying pathophysiology of this disorder 
[10]. While the old criteria conceptualized FMS as peripheral musculoskeletal 
condition, the new criteria account better for the role of the central nervous 
system (CNS) in the etiology of FMS. In addition, they simplify the diagnosis in 
primary care and integrate the diversity of symptoms (somatic and behavioral) 
associated with FMS [10] better.
The population prevalence of FMS in industrialized countries has been reported 
to range from 0.5 to 4% [11], with a ratio of 3.5% in women to 0.5% in men [12]. 
FMS is one of the most prevalent chronic pain conditions [12]. Like other chronic 
pain conditions, FMS often leads to disability, affective disturbance and poor quality 
of life and is also associated with high direct and indirect disease related costs [13]. 
The etiology of FMS is widely unknown; and this disorder remains very difficult 
to treat. However, accumulated evidence over the past years suggests that a wide 
range of factors that could potentially underlie the disorder, including dysfunctions 
of the central CNS and autonomic nervous systems, neurotransmitters, hormones, 
immune system, external stressors, psychiatric aspects and others [14]. Although 
there is increasing evidence for changes in the CNS, FMS is differentiated from 
neuropathic pain as there is no evidence for a primary lesion or disease of the 
somatosensory system in FMS [15]. It has been hypothesized however that FMS and 
neuropathic pain phenomena may be variations of the same condition [16, 17] with 
many common features such as precipitation or aggravation by stress, as well as com-
plaining about similar symptoms such as tingling, numbness, cutaneous hyperalgesia 
or pain attacks [18]. Finally, the recent evidence for impaired small fiber function in 
FMS patients also points towards a neuropathic nature of pain in FMS [19].
1.3 Challenges for the treatment of FMS
Despite this high clinical significance, the neural correlates and the interaction 
between psychological and neurobiological processes in the pathophysiology of 
FMS are still poorly understood, which in turn makes the development of treat-
ment strategies difficult. At pharmacological level, three medications have been 
approved by the FDA for the treatment of fibromyalgia [20]: one anti-epileptic 
drug (pregabalin) and two antidepressive drugs (duloxetine and milnacipran). 
Interestingly, all of them directly act on the CNS. However, recent research indicates 
that current pharmacological treatments are not really effective in the reduction of 
pain or improvement in function in patients with FMS, and there is still a lack of 
effective drugs for the treatment of FMS over time [21]. Furthermore, the current 
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evidence-based guidelines for the treatment of patients with FMS are inconsistent 
[22]. Finally, recent meta-analyses conclude that optimal treatment interventions 
should include components aimed at enhancing adaptive cognitive and behavioral 
responses [23, 24], and large improvements have been observed with treatment 
plans that include non-pharmacologic interventions [25]. This is in line with the 
current international guidelines that recommend aerobic exercise, cognitive-
behavioral therapy (CBT), and multicomponent treatment as first choice for the 
care of FMS patients [22]. These conclusions are also in agreement with the current 
state of research concerning the treatment of chronic pain in general. For chronic 
pain also, most of the available medications show poor efficacy, are accompanied by 
severe side effects with chronic use, or, in the case of opioids, may lead to depen-
dence or addiction [26]. In addition, chronic pain is commonly associated with 
comorbid affective disorders (e.g. anxiety, depression) and cognitive deficits (e.g. 
memory impairment), suggesting on one hand critical involvement of higher order 
neural brain processing [27], and on the other hand the necessity to develop specific 
interventions targeting the comorbid mental disorder the mood and cognitive 
dysfunctions as well (see for instance [28].
This chapter will therefore focus on specific neural changes associated with 
chronic pain in general, and with FMS in particular, that could bring new advances 
in the development of efficient treatment strategies for these conditions. These 
neural factors concern the changes in the dopamine function observed in chronic 
pain and their implication for responses to rewarding stimuli.
2. The dopamine function in chronic pain and in fibromyalgia
2.1 Changes in dopamine function in chronic pain disorders and in FMS
Among the neural changes observed in chronic pain, there is increasing evidence 
for alterations in the dopamine (DA) system. These changes seem to be related with 
a reduction of the DA function in chronic pain conditions. Evidence supporting 
a hypodopaminergic state in chronic pain comes from both preclinical [29] and 
clinical data [30, 31]. For instance, alterations in the DA function were described 
in burning mouth syndrome and atypical facial pain [32, 33]. The high incidence 
of central pain (including neuropathic pain) in patients suffering from Parkinson’s 
disease suggests that pain is a common symptom in patients with hypofunctional 
nigrostriatal dopaminergic pathways [34], and that low DA may contribute to 
increased pain [35]. Similar changes were observed in FMS. For instance, two 
PET-studies showed that self-reported pain induced by hypertonic saline injection 
in healthy volunteers correlated with the amount of DA released in the basal ganglia 
[32, 33]. These findings suggest an involvement of DA activity in endogenous 
analgesia [36, 37]. In contrast to healthy subjects, FMS patients did not show DA 
release in response to noxious stimulation [36]. Furthermore, activity of the ventral 
tegmental area was decreased during both pain perception and expectation of pain 
relief in FMS patients in an fMRI (functional Magnetic Resonance Imaging) study 
[30] suggesting a dysregulation of DA signaling in these patients. A previous study 
by our group added evidence of a reduced DA function in FMS patients, and indi-
cated a role of depression in the relation between pain perception and DA changes 
[38]. Our main results yielded that investigation of the DA function allows differen-
tiating between FMS patients with and without depression, as well as between FMS 
patients and healthy subjects and that the neurobiological mechanisms underlying 
depressive symptoms in FMS patients with depression are different from the ones 
reported in depressed patients without pain.
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Even among healthy individuals, low DA receptor availability has been associ-
ated with enhanced pain responses [39]; and DA depletion has been shown to 
influence pain affect and not the sensory aspects of acute painful stimuli [40]. This 
could suggest that in chronic pain, a low DA function could lead to changes in affec-
tive states [41]. Additionally, recent studies using animal models of neuropathic 
pain link changes in DA receptor signal transduction, the amount of released DA 
and other neurochemical adaptations in the midbrain DA circuit with depression-
like behaviors and reduced motivation [42–44]. This is in line with findings 
showing that aberrant dopaminergic transmission in the mesolimbic DA network 
underlay several mood disorders [45]. On the other hand, accumulating evidence 
suggests that the mesolimbic DA system modulates the perception of nociceptive 
information, and the affective symptoms of chronic pain [46]. Notably, several 
diseases associated with dysfunctional DA transmission are comorbid with chronic 
pain, including Parkinson’s disease, drug addiction and major depression [41].
Taken together, there are now multiple lines of evidence showing that chronic 
pain, including FMS, leads to a hypodopaminergic state that results in enhanced 
pain sensitivity and might impair motivated behavior [47]. In addition, DA is 
involved in descending inhibitory modulation of pain transmission, which is an 
additional link between hypodopaminergia and chronic pain [48]. Strategies to 
restore dopamine signaling may therefore represent a novel approach to manage 
pain symptoms in FMS.
2.2 Alterations of the brain reward circuit in chronic pain and FMS
It is well documented that the mesocorticolimbic and mesostriatal DA sys-
tems play a role in the processing of reward information [49–51], even if other 
neurotransmitter systems, such as the opiate system, are also important in 
the mediation of reward [52]. Recent studies indicating that alterations of the 
mesolimbic reward pathway contribute to the pathology of chronic pain [53, 54] 
suggest a neurobiological overlap between pain processing and the reward cir-
cuitry. Pain and reward can be regarded as opponent processes that interact and 
influence each other [55]. Several studies demonstrated that rewards, including 
pleasurable stimuli and activities and positive affective states have an analgesic 
effect and decrease pain sensitivity [55–58]. Finally, some findings suggest that 
pain and reward are mediated by similar neural pathways in the central nervous 
system and that these pathways are related to both the DA and the opioid sys-
tems [55, 58]. At a neurochemical level, several preclinical and clinical findings 
suggest that chronic pain leads to a hypodopaminergic condition in the reward 
circuitry, resulting in the diminution of the hedonic tone (see Section 2.1). This 
suggests that the brain reward center might play a key role in the modulation of 
nociception, and that adaptions in dopaminergic circuitry may affect several 
sensory and affective components of chronic pain syndromes. These adaptations 
involve changes in the levels of released DA, as well as postsynaptic changes in 
the levels of receptors and signal transduction molecules [59].
After having established that pain and reward might influence each other 
through the implication of the DA system, the next subsections will provide an 
overview of the findings reporting changes in the responses to reward in chronic 
pain first, and then secondly specifically in FMS.
2.2.1 Changes in the brain reward circuitry in chronic pain
Findings from functional neuroimaging studies indicate that a network of brain 
regions, including the orbitofrontal cortex, the ventral (specifically the nucleus 
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accumbens, Nacc) and dorsal striatum, the amygdala and the anterior cingulate 
gyrus, specifically interact to process reward information [60] and form the 
so-called cerebral reward system. In chronic pain, alterations in brain structural 
features, functional connectivity, or activity of these regions have been reported 
[37, 46, 61]. Additional evidence from clinical studies links chronic pain conditions 
to aberrant functioning of circuits involved in mood and motivation, including the 
dopamine brain reward center [62, 63]. The neural changes observed in regions 
associated with the cerebral reward system could provide a possible explanation for 
the high incidence of comorbid affective disorders in chronic pain patients [59]. In 
summary, the reported empirical evidence suggests that pain, in particular chronic 
pain, impairs several aspects of reward processing: (1) chronic pain is associated 
with anhedonia, that is, the inability to enjoy pleasurable activities [44, 64]; (2) 
decreased reward sensitivity and/or decreased motivation was observed in rats 
with neuropathic pain [65]; (3) impaired operant learning of pain sensitization and 
habituation was found in FMS patients [66]; and (4) impaired decision making 
based on reward and punishment was reported in patients with chronic back pain 
and complex regional pain syndrome (CPRS) [67]. Decreased reward responsivity 
may therefore underlie a key system mediating anhedonia and depression com-
mon with chronic pain [41, 68, 69]. This is highly relevant since the prevalence of 
depression in chronic pain exceeds 20% [70] and often includes anhedonia [44, 
64]. Anhedonia is also one of the cardinal symptoms of depression, and has been 
hypothesized to be associated with an hypofunction of the DA system, what in 
turn could affect the neural processing of rewarding information [51]. As a matter 
of fact, a large body of research has evidenced reduced neural activation as well as 
reduced DA transmission in response to reward information in patients with major 
depressive disorder (MDD) (see for instance [71–73]). Recent evidence from animal 
studies suggest that suppression of dopaminergic neurotransmission in the meso-
limbic reward circuit may be a common neuroplastic change underlying chronic 
pain and depression that develops in a time-dependent manner [74].
2.2.2 Changes in the brain reward circuitry in FMS
To our knowledge, there is so far only one study that has directly investigated the 
DA responses to reward in vivo in FMS patients [59]. In this research of our group, 
we used the [11C]Raclopride positron emission tomography (PET), a radiotracer 
that is sensitive to changes in intrasynaptic DA concentrations while participants 
were performing a slot machine compared FMS participants with and without 
depression with healthy controls (all women). We expected the patients’ groups to 
have reduced DA responses to reward, expressed as a larger Raclopride binding in 
the FMS groups of participants than in the group of healthy controls. In addition, 
we expected this alteration to be stronger in FMS patients with than in FMS patients 
without depression. However, our results showed, at the contrary of our hypoth-
esis, the greatest [11C]Raclopride displacement in response to rewards in the group 
of FMS participants with depression [59], which is thought to reflect the largest 
increase in DA transmission. This can be explained by a greater increase of synaptic 
DA transmission or by adaptative receptor changes in this group, but necessitate 
further investigation to be more clearly understood. Our results also indicated 
that the depression associated with FMS has different neurochemical correlates 
as primary major depressive disorder. More specifically, a previous study by our 
group [71] using the same methodology found no [11C]Raclopride displacement in 
response to rewards in a group of MDD patients without pain symptoms, suggest-
ing reduced DA responses in the brain of depressive patients at the contrary of our 
group of FMS patients with depression. In conclusion, there is first evidence for a 
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hypodopaminergic state in FMS and an alteration of the neural reactions to reward 
mediated by the DA system. Even if the exact mechanisms by which the brain 
reward center modulates chronic pain resp. FMS are not completely established yet, 
this opens new treatment avenues. Certainly, pharmacological interventions target-
ing the DA system could be an option. However, we will focus here on psychological 
interventions that might directly work on the behavioral responses to reward and in 
turn might be able to restore the DA function.
3. Implications for the treatment of FMS
The current international guidelines for the treatment of FMS all recommend 
psychological interventions, more specifically cognitive behavioral therapy (CBT), 
as one of the treatments of choice for the care of FMS patients [22]. According to 
a recent meta-analysis, CBT is significantly better than the other psychological 
interventions for which randomized controlled trials exist [75]. The effects of CBT 
are relatively small but robust and similar to those reported for other pain and 
drug treatments [75], but have limited success in ameliorating affective and social 
complaints in FMS patients [25, 75, 76]. There is therefore a need for the develop-
ment of new CBT methods targeting specific behavioral, emotional or cognitive 
processes in the treatment of chronic pain. Recently, the so-called “third wave” 
cognitive-behavior therapies [77] have integrated mindfulness-based cognitive 
therapy as additional intervention. Mindfulness is defined as “a process of bringing 
a certain quality of attention to moment-by-moment experience” [78]. Mindfulness 
capacity can be developed using various meditation techniques that originate from 
Buddhist spiritual practices [78]. A growing body of research has demonstrated 
that mindfulness-based interventions are clinically effective for a wide range of 
problematic conditions (for a review see Grossmann et al. [78]) and have gained 
increasingly wide use for the treatment of chronic pain conditions including FMS, 
showing promising results [79, 80]. A recent systematic review indicates a moderate 
significant effect for mindfulness on the amelioration of mood-related outcomes 
in FMS [81]. Among these new interventions, Mindfulness-Oriented Recovery 
Enhancement (MORE) is a mental training program that unites complementary 
aspects of mindfulness training, CBT and positive psychological principles into 
an integrative treatment strategy [82]. MORE was originally designed as a behav-
ioral medical intervention for addictive behaviors [83, 84], but was more recently 
adapted to address chronic pain among individuals receiving long-term opioid 
analgesic therapy [82]. A randomized clinical trial showed that MORE significantly 
reduces pain symptoms [82] in chronic pain patients. First empirical evidence sug-
gests that MORE is also associated with behavioral and neurophysiological changes 
in reward processing [85, 86], suggesting that interventions working on the reward 
system might be efficient for pain reduction.
4. Conclusion
In conclusion, CBT-based treatments specifically working on the awareness of 
pleasant experiences, such as MORE, seem to be effective in restoring the behav-
ioral and neural responses to reward and also to diminish pain symptoms in chronic 
pain patients. Although not yet tested in FMS patients, this could be a promising 
new treatment alternative for this group of patients, in which changes in the DA 
function and in the responses to reward have been evidenced, but for whom no 
efficient treatment is available so far.
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